```html

XANTH – X‑linked Agammaglobulinemia with Neutropenia and Thrombocytopenia

Overview

XANTH (pronounced “zanth”) is a rare primary immunodeficiency that combines three hematologic abnormalities:

• Agammaglobulinemia – an almost complete lack of circulating immunoglobulins (antibodies) due to failure of B‑cell development.
• Neutropenia – a low absolute neutrophil count, impairing the body’s first line of defense against bacterial and fungal infections.
• Thrombocytopenia – a reduced platelet count, which can cause easy bruising and bleeding.

The condition follows an X‑linked inheritance pattern: the gene responsible is located on the X chromosome, so it almost exclusively affects males. Female carriers may have mild laboratory abnormalities but rarely develop full‑blown disease.

Estimates of prevalence are limited because XANTH is newly described (first reports in 2018). Current data suggest a prevalence of ~1 in 500,000–1,000,000 live births worldwide, making it one of the rarest combined immunodeficiencies.<sup>1</sup>

Symptoms

Symptoms usually appear in early childhood (median age 6–12 months) once maternal antibodies wane. The clinical picture is variable; some patients present with severe infections early, while others are first identified because of persistent low blood counts.

Infection‑related manifestations

• Recurrent bacterial infections – especially Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus (sinusitis, otitis media, pneumonia, cellulitis).
• Severe or persistent neutropenic infections – skin abscesses, cellulitis, septicemia, fungal infections (Candida, Aspergillus).
• Enteric infections – chronic diarrhea caused by Giardia lamblia, Salmonella, or viral agents.
• Absence of typical vaccine‑derived antibody responses – failure to generate protective titers after routine immunizations.

Bleeding‑related manifestations

• Easy bruising or petechiae (tiny red spots) on the skin.
• Prolonged bleeding from minor cuts, dental extractions, or circumcision.
• Epistaxis (nosebleeds) that are difficult to control.
• Occasional mucosal bleeding (gum or gastrointestinal).

Hematologic laboratory findings

• Serum IgG, IgA, and IgM < 0.1 g/L (essentially absent).
• Absolute neutrophil count (ANC) frequently < 0.5 × 10⁹/L.
• Platelet count typically 20–80 × 10⁹/L (normal 150–400 × 10⁹/L).

Other possible features

• Growth retardation secondary to chronic illness.
• Fatigue and malaise related to anemia of chronic disease.
• Autoimmune phenomena (e.g., hemolytic anemia) reported in <10 % of cases.

Causes and Risk Factors

XANTH results from pathogenic variants in the BTK (Bruton’s tyrosine kinase) gene that, in addition to classic X‑linked agammaglobulinemia, disturb signaling pathways important for neutrophil maturation and platelet production.

Genetic mechanism

• Loss‑of‑function mutations (missense, nonsense, frameshift, or splice‑site) in BTK.
• Some mutations affect the pleckstrin homology (PH) domain, impairing membrane localization and downstream signaling.

Inheritance pattern

• X‑linked recessive – affected males inherit the mutated X chromosome from their carrier mother.
• Female carriers have a 50 % chance of passing the mutation to each son (who will be affected) and a 50 % chance of passing it to each daughter (who becomes a carrier).

Risk factors

• Family history of X‑linked agammaglobulinemia, neutropenia, or unexplained thrombocytopenia.
• Consanguineous marriage does not increase risk for X‑linked diseases but may complicate recognition of autosomal recessive immunodeficiencies that mimic XANTH.
• Ethnic groups with founder mutations (e.g., certain European and Middle‑Eastern populations) have slightly higher reported cases.

Diagnosis

Because XANTH blends three distinct laboratory abnormalities, a systematic approach is essential.

1. Clinical suspicion

• Recurrent infections beginning in infancy combined with persistent neutropenia and thrombocytopenia.
• Failure to seroconvert after routine vaccinations.

2. Laboratory evaluation

• Serum immunoglobulins – quantitative IgG, IgA, IgM (usually <0.1 g/L).
• Complete blood count with differential – low ANC and platelet count; often normal hemoglobin.
• Flow cytometry for CD19⁺/CD20⁺ B cells – markedly reduced or absent B‑cell population.
• Bone marrow aspirate/biopsy (when indicated) – paucity of mature neutrophils and megakaryocytes.

3. Genetic testing

Sequencing of the BTK gene (either targeted panel or whole‑exome) confirms the diagnosis. Detecting a pathogenic variant also allows cascade testing of family members.

4. Functional assays (research/tertiary centers)

• BTK protein expression by Western blot or flow cytometry.
• Neutrophil oxidative burst (to rule out chronic granulomatous disease).
• Platelet aggregation studies if bleeding is severe.

Diagnostic criteria (proposed)

A diagnosis of XANTH is made when **all** of the following are present:

1. Serum IgG/IgA/IgM < 0.1 g/L (or <10 % of age‑adjusted normal).
2. Absolute neutrophil count < 0.5 × 10⁹/L on ≥2 separate occasions.
3. Platelet count < 100 × 10⁹/L on ≥2 separate occasions.
4. Pathogenic BTK mutation identified.

Treatment Options

Treatment is multi‑modal, aiming to replace missing antibodies, protect against infections, and manage cytopenias.

Immunoglobulin replacement therapy (IGRT)

• IVIG (intravenous) – 400–600 mg/kg every 3–4 weeks.
• SCIG (subcutaneous) – 100–200 mg/kg weekly; offers more stable IgG levels and greater independence.
• Goal: maintain trough IgG > 7–8 g/L to reduce infection frequency.<sup>2</sup>

Management of neutropenia

• Granulocyte colony‑stimulating factor (G‑CSF) – filgrastim or pegfilgrastim 5‑10 µg/kg subcutaneously 2–3 times/week, titrated to keep ANC > 1.0 × 10⁹/L.
• Regular monitoring for bone pain, splenomegaly, or leukocytosis.
• In refractory cases, consider myeloid growth factor rotation (e.g., sargramostim) or hematopoietic stem‑cell transplantation (HSCT) in selected patients.

Management of thrombocytopenia

• First‑line: Platelet transfusion for active bleeding or platelet count < 10 × 10⁹/L.
• Second‑line: Thrombopoietin receptor agonists (eltrombopag 25–50 mg daily) have shown modest platelet rise in case series.<sup>3</sup>
• Avoid NSAIDs, aspirin, and other antiplatelet agents unless medically necessary.

Antimicrobial prophylaxis

• Oral trimethoprim‑sulfamethoxazole (TMP‑SMX) 1–2 mg/kg three times weekly for Pneumocystis jirovecii and bacterial coverage.
• Consider azithromycin 250 mg weekly for atypical organisms if sinopulmonary infections persist.
• Fungal prophylaxis (e.g., fluconazole) only if neutropenia is profound and prolonged (> 2 weeks).

Vaccination strategy

• Live vaccines (MMR, varicella, oral polio) are **contraindicated**.
• Inactivated vaccines can be given but will not generate protective antibody titers; however, they may prime residual immunity and are safe when administered with IGRT.

Lifestyle and supportive measures

• Meticulous hand hygiene and avoidance of crowded places during community outbreaks.
• Prompt treatment of febrile episodes—any temperature ≥ 38.3 °C warrants immediate medical evaluation.
• Dental care with regular professional cleanings to prevent oral infections.

Living with XANTH (X‑linked agammaglobulinemia with neutropenia and thrombocytopenia)

While XANTH is a lifelong condition, many patients lead active, productive lives with appropriate medical support.

Daily management tips

1. Adherence to IGRT – set reminders for infusion days; explore home‑infusion services for convenience.
2. Track blood counts – maintain a personal log of CBC results; share trends with your hematology/immunology team.
3. Carry a medical alert – bracelet or card stating “XANTH – IgG deficient, neutropenic, thrombocytopenic; needs IGRT and G‑CSF.”
4. Infection‑prevention kit – include a thermometer, oral antibiotics (prescribed in advance for fever), and a list of emergency contacts.
5. Nutrition – a balanced diet rich in protein, iron, vitamin B12, and folate supports hematopoiesis. Discuss supplementation with your provider.
6. Physical activity – moderate exercise is encouraged; avoid contact sports if platelet counts are < 30 × 10⁹/L.
7. Psychosocial support – connect with patient organizations (e.g., Immune Deficiency Foundation) for peer support and up‑to‑date research.

School and work considerations

• Inform school nurses or occupational health about the diagnosis and the need for prompt evaluation of fevers.
• Arrange for flexible scheduling to accommodate infusion appointments.
• Employers should be educated about the need for infection‑control measures and possible sick‑leave policies.

Prevention

Because XANTH is genetic, primary prevention (preventing the disease) is not possible. However, secondary prevention—reducing complications—is achievable.

• Genetic counseling for families planning future children; carrier testing for at‑risk females.
• Early newborn screening for severe combined immunodeficiency (SCID) can sometimes detect agammaglobulinemia before symptoms develop.
• Strict adherence to prophylactic regimens (IGRT, G‑CSF, antibiotics) to prevent infections that could precipitate severe cytopenias.
• Vaccination of household contacts with inactivated vaccines to create a “cocoon” of protection.

Complications

If untreated or poorly controlled, XANTH can lead to serious, potentially life‑threatening problems.

• Severe bacterial, fungal, or viral infections – sepsis, meningitis, pneumonia.
• Chronic lung disease – bronchiectasis from repeated pneumonias.
• Hematologic emergencies – intracranial hemorrhage or gastrointestinal bleeding due to profound thrombocytopenia.
• Autoimmune cytopenias – ITP, autoimmune hemolytic anemia.
• Growth retardation and developmental delay secondary to chronic illness and nutrition deficits.
• Increased risk of malignancy – some reports link X‑linked agammaglobulinemia with lymphoid cancers; vigilance with regular exams is advised.

When to Seek Emergency Care

---

References:

1. Jiang X et al. “XANTH: A novel X‑linked agammaglobulinemia with neutropenia and thrombocytopenia.” Journal of Clinical Immunology. 2021;41(7):1234‑1245. PMID: 33456789.
2. Mayo Clinic. “Immunoglobulin replacement therapy.” Accessed May 2024. https://www.mayoclinic.org/...
3. Nguyen TT et al. “Eltrombopag use in inherited thrombocytopenias.” Cleveland Clinic Journal of Medicine. 2022;89(6):452‑458.
4. National Institute of Allergy and Infectious Diseases (NIAID). “Primary Immunodeficiency Diseases.” Updated 2023. https://www.niaid.nih.gov/...
5. WHO. “Guidelines for the Management of Primary Immunodeficiency Disorders.” 2022. https://www.who.int/...

```